CHMP recommends Olumiant approval for alopecia areata

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Olumiant for the treatment of alopecia areata, Eli Lilly and Company announced in a press release.
If approved, Olumiant (baracitinib) would be the first oral treatment and Janus kinase inhibitor approved for alopecia areata in the European Union.
The opinion was based on the phase 3 BRAVE-AA1 and BRAVE-AA2 trials, in which one out of three patients treated with Olumiant 4 mg experienced at least an 80% improvement in scalp hair coverage.
“We’re proud of today’s

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Olumiant for the treatment of alopecia areata, Eli Lilly and Company announced in a press release.
If approved, Olumiant (baracitinib) would be the first oral treatment and Janus kinase inhibitor approved for alopecia areata in the European Union.
The opinion was based on the phase 3 BRAVE-AA1 and BRAVE-AA2 trials, in which one out of three patients treated with Olumiant 4 mg experienced at least an 80% improvement in scalp hair coverage.
“We’re proud of today’s